David Shaw’s scPharmaceuticals SCPH Stock Holding History

David Shaw’s Portfolio SCPH Stock Details SCPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-43,935	Closed	-$545K	–	3870
2018 Q1	$545K	Buy	+43,935	New	+$590K	﹤0.01%	2837

Other funds holding SCPH

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

David Shaw's SCPH Position: Q2 2018 in Review

David Shaw sold out of scPharmaceuticals (SCPH) in Q2 2018, closing a stake of 43,935 shares — an estimated $545K sold.

David Shaw first reported a position in SCPH in Q1 2018 and held it in 1 quarter. The position peaked at $545K in Q1 2018. 41 funds tracked by Wall St. Rank hold SCPH as of Q2 2018.

David Shaw reported no remaining scPharmaceuticals position as of Q2 2018 after selling out during the quarter.
David Shaw sold 43,935 scPharmaceuticals shares in Q2 2018, an estimated $545K.
David Shaw first reported a position in scPharmaceuticals in Q1 2018 and held it in 1 quarter.
David Shaw's scPharmaceuticals position peaked at $545K in Q1 2018.
41 funds tracked by Wall St. Rank held scPharmaceuticals as of Q2 2018.

Based on D.E. Shaw & Co's 13F filing for Q2 2018, filed 14 Aug 2018.